Page 2008 - Williams Hematology ( PDFDrive )

1982 Part XII: Hemostasis and Thrombosis Chapter 115: Vascular Function In Hemostasis 1983

219. Loscalzo J, Weinfeld M, Fless G, Scanu AM: Lipoprotein(a), fibrin binding, and plas- 255. Miles A, Liaskou E, Eksteen B, et al: CCL25 and CCL28 promote alpha4 beta7-integ-
minogen activation. Arteriosclerosis 10:240–245, 1990. rin-dependent adhesion of lymphocytes to MAdCAM-1 under shear flow. Am J Physiol
220. Lawn RM, Wade DP, Hammer RE, et al: Atherogenesis in transgenic mice expressing Gastrointest Liver Physiol 294:G1257–G1267, 2008.
human apolipoprotein(a). Nature 360:670–672, 1992. 256. Bargatze RF, Kurk S, Butcher EC, Jutila MA: Neutrophils roll on adherent neutrophils
221. Boonmark NW, Lou XJ, Schwartz K, et al: Modification of apolipoprotein(a) lysine bound to cytokine-induced endothelial cells via L-selectin on the rolling cells. J Exp
binding site reduces atherosclerosis in transgenic mice. J Clin Invest 100:558–564, 1997. Med 180:1785–1792, 1994.
222. Kraus JP: Molecular basis of phenotype expression in homocystinuria. J Inherit Metab 257. Walcheck B, Moore KL, McEver RP, Kishimoto TK: Neutrophil-neutrophil interactions
Dis 17:383–390, 1994. under hydrodynamic shear stress involve L-selectin and PSGL-1. J Clin Invest 98:1081–1087,
223. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG: A quantitative assessment of 1996.
plasma homocysteine as a risk factor for vascular disease. JAMA 274:1049–1057, 1995. 258. Muller WA: Migration of leukocytes across the vascular intima. Molecules and mecha-
224. Refsum H, Ueland PM, Nygard O, Vollset SE: Homocysteine and cardiovascular dis- nisms. Trends Cardiovasc Med 5:15–20, 1995.
ease. Annu Rev Med 49:31–62, 1998. 259. Sullivan DP, Muller WA: Neutrophil and monocyte recruitment by PECAM, CD99, and
225. Ueland PM, Loscalzo J: Homocysteine and cardiovascular risk: The perils of reduction- other molecules via the LBRC. Semin Immunopathol 36:193–209, 2014.
ism in a complex system. Clin Chem 58:1623–1625, 2012. 260. Ley K, Laudanna C, Cybulsky MI, Nourshargh S: Getting to the site of inflammation:
226. Hajjar KA: Homocysteine-induced modulation of tissue plasminogen activator binding The leukocyte adhesion cascade updated. Nat Rev Immunol 7:678–689, 2007.
to its endothelial cell membrane receptor. J Clin Invest 91:2873–2879, 1993. 261. Muller WA, Ratti CM, McDonnell SL, Cohn ZA: A human endothelial cell-restricted,
227. Hajjar KA, Mauri L, Jacovina AT, et al: Tissue plasminogen activator binding to externally disposed plasmalemmal protein enriched in intercellular junctions. J Exp
the annexin II tail domain: Direct modulation by homocysteine. J Biol Chem 273: Med 170:399–414, 1989.
9987–9993, 1998. 262. Newman PJ, Berndt MC, Gorski J, et al: PECAM-1 (CD31) cloning and relation to
228. Jacovina AT, Deora AB, Ling Q, et al: Homocysteine inhibits neoangiogenesis in mice adhesion molecules of the immunoglobulin gene superfamily. Science 247:1219–1222,
through blockade of annexin A2-dependent fibrinolysis. J Clin Invest 119:3384–3394, 1990.
2009. 263. Muller WA, Weigl SA, Deng X, Phillips DM: PECAM-1 is required for transendothelial
229. Miyakis S, Lockshin MD, Atsumi T, et al: International consensus statement on an migration of leukocytes. J Exp Med 178:449–460, 1993.
update of the classification criteria for definite antiphospholipid syndrome (APS). J 264. Huang AJ, Manning JE, Bandak TM, et al: Endothelial cell cytosolic free calcium regu-
Thromb Haemost 4:295–306, 2006. lates neutrophil migration across monolayers of endothelial cells. J Cell Biol 120:1371–
230. Cockrell E, Espinola RG, McCrae KR: Annexin A2: Biology and relevance to the anti- 1380, 1993.
phospholipid syndrome. Lupus 17:943–951, 2008. 265. Liao F, Ali J, Greene T, Muller WA: Soluble domain 1 of platelet-endothelial cell adhe-
231. Ma K, Simantov R, Zhang JC, et al: High affinity binding of beta 2-glycoprotein I to sion molecule (PECAM) is sufficient to block transendothelial migration in vitro and
human enodhtelial cells is mediated by annexin II. J Biol Chem 275:15541–15548, 2000. in vivo. J Exp Med 185:1349–1357, 1997.
232. Zhang J, McCrae KR: Annexin A2 mediates endothelial cell activation by antiphospho- 266. Liao F, Huynh HK, Eiroa A, et al: Migration of monocytes across endothelium and
lipid/anti-beta2 glycoprotein I antibodies. Blood 105:1964–1969, 2005. passage through extracellular matrix involve separate molecular domains of PECAM-1.
233. Raschi E, Testoni C, Bosisio D, et al: Role of the My88 transduction signaling pathway J Exp Med 182:1337–1343, 1995.
in endothelial activation by antiphospholipid antibodies. Blood 101:3295–3500, 2003. 267. Ostermann G, Weber KSC, Zernecke A, et al: JAM-1 is a ligand for the b2 integrin LFA-1
234. Romay-Penabad Z, Montiel-Manzano MG, Pappalardo E, et al: Pathogenic effects involved in transendothelial migration of leuocytes. Nat Immunol 3:151–158, 2002.
of antiphospholipid antibodies are ameliorated in annexin A2 deficient mice. Blood 268. Johnson-Leger C, Aurrand-Lions M, Beltraminelli N, et al: Junctional adhesion mol-
i114:3074–3083, 2009. ecule-2 (JAM-2) promotes lymphocyte transendothelial migration. Blood 100:2479–
235. von Bruhl ML, Stark K, Steinhart A, et al: Monocytes, neutrophils, and platelets cooperate 2486, 2002.
to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 209:819–835, 2012. 269. Feng D, Nagy JA, Pyne K, et al: Neutrophils emigrate from venules by a transendothelial
236. Polgar J, Matuskova J, Wagner DD: The P-selectin, tissue factor, coagulation triad. J cell pathway in response to fMLP. J Exp Med 187:903–915, 1999.
Thromb Haemost 3:1590–1596, 2005. 270. Carman CV, Springer TA: Trans-cellular migration: Cell-cell contacts get intimate. Curr
237. Ardoin SP, Shanahan JC, Pisetsky DS: The role of microparticles in inflammation and Opin Cell Biol 20:533–540, 2008.
thrombosis. Scand J Immunol 66:159–165, 2007. 271. Bixel MG, Petri B, Khandoga AG, et al: A CD99-related antigen on endothelial cells
238. George FD: Microparticles in vascular diseases. Thromb Res 122:S55–S59, 2008. mediates neutrophil, but not lymphocyte extravasation in vivo. Blood 109:5327–5336,
239. Lechner D, Weltermann A: Circulating tissue factor-exposing microparticles. Thromb 2009.
Res 122:S47–S54, 2008. 272. Dufour EM, Deroche A, Bae Y, Muller WA: CD99 is essential for leukocyte diapedesis
240. Peerschke EI, Yin W, Ghebrehiwet B: Platelet mediated complement activation. Adv in vivo. Cell Commun Adhes 15:351–363, 2008.
Exp Med Biol 632:81–91, 2008. 273. Schenkel AR, Mamdouh Z, Chen X, et al: CD99 plays a major role in the migration of
241. Muller WA: Leukocyte-endothelial cell interactions in leukocyte transmigration and monocytes through endothelial junctions. Nat Immunol 3:2479–2486, 2002.
the inflammatory response. Trends Immunol 24:326–333, 2003. 274. Marchesi VT, Florey HW: Electron micrographic observations on the emigration of
242. Angiari S, Donnarumma T, Rossi B, et al: TIM-1 glycoprotein binds the adhesion leukocytes. Q J Exp Physiol Cogn Med Sci 45:343–347, 1960.
receptor P-selectin and mediates T cell trafficking during inflammation and autoim- 275. Schnoor M, Lai FP, Zarbock A, et al: Cortactin deficiency is associated with reduced
munity. Immunity 40:542–553, 2014. neutrophil recruitment but increased vascular permeability in vivo. J Exp Med
243. Wilkins PP, Moore KL, McEver RP, Cummings RD: Tyrosine sulfation of P-selectin 208:1721–1735, 2011.
glycoprotein ligand-1 is required for high affinity binding to P-selectin. J Biol Chem 276. Leeuwenberg JFM, von Asmuth EJ, Jeunhomme TM, Buurman WA: IFN-gamma regu-
270:22677–22680, 1995. lates the expression of the adhesion molecule ELAM-1 and IL-6 production by human
244. Snapp KR, Craig R, Herron M, et al: Dimerization of P-selectin glycoprotein ligand-1 endothelial cells in vitro. J Immunol 145:2110–2114, 1990.
(PSGL-1) required for optimal recognition of P-selectin. J Cell Biol 142:263–270, 1998. 277. Strindall J, Lundblad A, Pahlsson P: Interferon-gamma enhancement of E-selectin expres-
245. Lalor P, Nash GB: Adhesion of flowing leucocytes to immobilized platelets. Br J Haematol 89. sion on endothelial cells is inhbiited by monensin. Scand J Immunol 46:338–343, 1997.
246. Tanaka Y, Adams DH, Hubscher S, et al: T-cell adhesion induced by proteoglycan-im- 278. Ley K, Arbones ML, Bosse R, et al: Sequential contribution of L- and P-selectin to leu-
mobilized cytokine MIP-1 beta. Nature 361:79–82, 1995, 1993. kocyte rolling in vivo. J Exp Med 181:669–675, 1995.
247. Lo SK, Lee S, Ramos RA, et al: Endothelial-leukocyte adhesion molecule 1 stimulates 279. Khew-Goodall Y, Butcher E, Litwin MS, et al: Chronic expression of P-selectin on
the adhesive activity of leukocyte integrin CD3 (CD11B/CD18, Mac-1, alpha m beta 2) endothelial cells stimulated by the T-cell cytokine, interleukin-3. Blood 87:1432–1438,
on human neutrophils. J Exp Med 173:1493–1500, 1991. 1999.
248. Lorant DE, Patel KD, McIntyre TM, et al: Coexpression of GMP-140 and PAF by endo- 280. Yao L, Pan J, Setiadi H, et al: Interleukin-4 or oncostatin M induces a prolonged increase
thelium stimulated by histamine or thrombin: A juxtacrine system for adhesion and in P-selectin mRNA and protein in human endthelial cells. J Exp Med 184:81–92, 1996.
activation of neutrophils. J Cell Biol 115:223–234, 1991. 281. Jung U, Ley K: Regulation of E-selectin, P-selectin, and intercellular adhesion mole-
249. Huber AR, Kunkel SL, Todd RF, Weiss SL: Regulation of transendothelial neutrophil cule-1 expression in mouse cremaster vasculature. Microcirculation 4:311–319, 1997.
migration by endogenous interleukin-8. Science 254:99–102, 1991. 282. Pan J, Xia L, Yao L, McEver RP: Tumor necrosis factor-alpha- or lipopolysaccharide-
250. Tanaka Y, Albelda SM, Horgan KJ, et al: CD31 expressed on distinctive T cell subsets is a induced expression of the murine P-selectin gene in endothelial cells involves novel
preferential amplifier of beta 1 integrin-mediated adhesion. J Exp Med 176:245–253, 1992. kappaB sites and a variant activating transcription factor/cAMP response element.
251. Piali L, Albelda SM, Baldwin HS, et al: Murine platelet endothelial cell adhesion mole- J Biol Chem 273:10067–10077, 1998.
cule (PECAM-1/CD31) modulates beta2 integrins on lymphokine-activated killer cells. 283. Masinovsky B, Urdal D, Gallatin WM: IL-4 acts synergistically with IL-1 beta to pro-
Eur J Immunol 23:2464–2471, 1993. mote lymphocyte adhesion to microvascular endothelium by induction of vascular cell
252. Berman ME, Muller WA: Ligation of platelet/endothelial cell adhesion molecule 1 adhesion molecule-1. J Immunol 145:2886–2895, 1990.
(PECAM-1/CD31) on monocytes and neutrophils increases binding capacity of leuko- 284. Blease K, Seybold J, Adcock IM, et al: Interleukin-4 and lipopolysaccharide synergize
cyte CR3 (CD11b/CD18). J Immunol 154:299–307, 1995. to induce vascular adhesion molecule-1 expression in human lung microvascular endo-
253. Hynes RO: Integrins: Versatility, modulation, and signalling in cell adhesion. Cell thelial cells. Am J Respir Cell Mol Biol 18:620–630, 1998.
69:11–25, 1992. 285. Pober JS, Collins T, Gimbrone M, et al: Inducible expression of class II major histocom-
254. Carlos TM, Harlan JM: Leukocyte-endothelial cell adhesion molecules. Blood 84:2068– patibility complex antigens and the immunogenicity of vascular endothelium. Trans-
2101, 1994. plantation 41:141–146, 1986.

Kaushansky_chapter 115_p1967-1984.indd 1983 9/18/15 10:09 AM